Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals
Retrieved on:
Wednesday, July 12, 2023
Inflammation, CT, Plaque, NHS England, National Health Service, Cardiovascular disease, University Hospitals Cleveland Medical Center, CAD, Liverpool Heart and Chest Hospital NHS Foundation Trust, FAI, CCTA, Atherosclerosis, Milton Keynes University Hospital, Hospital, Patient, Oxford University Hospitals NHS Foundation Trust, Risk, Royal Wolverhampton NHS Trust, University Hospitals of Leicester NHS Trust, Algorithm, Artificial intelligence, NHS, Coronary artery disease, NICE, Pharmaceutical industry, Medical imaging, EU
OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
Key Points:
- OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
- The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
- The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
- "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".